French biotech receives Qualified Hit List

They have now received the so-called Qualified Hit List from the European Lead Factory for their innovative approach targeting the cytoskeleton regulation. Renaud Prudent, Chief Operating Officer of CELLIPSE, thanked the ELF teams involved:  'Despite some unexpected difficulties along the way, they managed to deliver the results that we anticipated. This will allow us to build a second chemistry asset programme, to strengthen our ongoing proprietary lead candidates portfolio of kinase inhibitors for myeloid leukemias.'

Interested? Read more on their website.